News | Robotic Systems | January 21, 2020

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

First robotic PCIs performed at Rheinland Klinikum Neuss Lukaskrankenhaus

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announced it has successfully completed its first robotic coronary angioplasties with its R-One robotic catheter guidance system in Germany. The Percutaneous coronary interventions (PCI) were performed by Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.

“I’m proud to be the first user of this brand new European robotic solution for PCI in Germany," Haude said. "These robotic interventions pave the way for a new era in interventional cardiology. The benefits brought by R-One are huge for practitioners and will drastically improve our working conditions, which will consequently benefit patient care. My team and I look forward to integrating this robotic-assisted platform for PCI into our day-to-day clinical practice.”

"Professor Haude has over 30 years experience in interventional cardiology and we rely on capitalizing on this kind of experience to develop clinical evidence and demonstrate all the benefits of our solution," said Philippe Bencteux, chairman and founder of Robocath.

These first procedures in Germany are an important strategic step, said Lucien Goffart, CEO of Robocath. He said interest from major industry players is a clear indicator of this, such as the recent purchased of Corindus by Siemens in 2019.
Founded in 2009 by Philippe Bencteux, M.D., Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its solutions aim to make medical procedures safer with reliable technologies, while complementing manual interventions.

R-One is the first solution developed by Robocath. It is designed to operate with precision and perform specific movements, creating better interventional conditions. It uses an open architectureto make it compatible with market-leading devices and cath labs. 

The system received European CE mark in February 2019 and started its clinical use in September 2019.

The company hopes to develop a remote treatment system for vascular emergencies.

Watch the VIDEO: First Robotic PCI Case in Germany With Robocath R-One System

For more information: www.robocath.com

 

Related Cath Lab Robot Content:

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

Robocath Successfully Carries Out First Robotic Coronary Angioplasties in Humans

Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System 
 

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major